0001193125-26-368286.txt : 20260826
0001193125-26-368286.hdr.sgml : 20260826
20260826160505
ACCESSION NUMBER: 0001193125-26-368286
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06c
FILED AS OF DATE: 20260826
DATE AS OF CHANGE: 20260826
EFFECTIVENESS DATE: 20260826
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aptevo Therapeutics Inc.
CENTRAL INDEX KEY: 0001671584
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
EIN: 811567056
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-595477
FILM NUMBER: 261322667
BUSINESS ADDRESS:
STREET 1: 2401 4TH AVE.
STREET 2: SUITE 1050
CITY: SEATTLE
STATE: WA
ZIP: 98121
BUSINESS PHONE: 206-838-0500
MAIL ADDRESS:
STREET 1: 2401 4TH AVE.
STREET 2: SUITE 1050
CITY: SEATTLE
STATE: WA
ZIP: 98121
D
1
primary_doc.xml
X0708
D
LIVE
0001671584
Aptevo Therapeutics Inc.
2401 4th Ave.
Suite 1050
Seattle
WA
WASHINGTON
98121
206-838-0500
DELAWARE
None
Corporation
true
Jeffrey
G
Lamothe
2401 4th Avenue
Suite 1050
Seattle
WA
WASHINGTON
98121
Executive Officer
Director
Marvin
L
White
2401 4th Avenue
Suite 1050
Seattle
WA
WASHINGTON
98121
Executive Officer
Director
Daphne
Taylor
2401 4th Avenue
Suite 1050
Seattle
WA
WASHINGTON
98121
Executive Officer
John
E
Niederhuber
2401 4th Avenue
Suite 1050
Seattle
WA
WASHINGTON
98121
Director
Daniel
J
Abdun-Nabi
2401 4th Avenue
Suite 1050
Seattle
WA
WASHINGTON
98121
Director
Grady
Grant III
2401 4th Avenue
Suite 1050
Seattle
WA
WASHINGTON
98121
Director
Zsolt
Harsanyi
2401 4th Avenue
Suite 1050
Seattle
WA
WASHINGTON
98121
Director
Barbara
Lopez Kunz
2401 4th Avenue
Suite 1050
Seattle
WA
WASHINGTON
98121
Director
Pharmaceuticals
No Revenues
- 06c
false
2026-08-12
false
true
true
false
0
Roth Capital Partners, LLC
15407
None
None
888 San Clemente Drive, Suite 400
Newport Beach
CA
CALIFORNIA
92660
All States
false
3472683
3472683
0
false
3
315001
0
We paid an additional $90,000 in placement agent expenses.
0
false
Aptevo Therapeutics Inc.
/s/Jeffrey G. Lamothe
Jeffrey G. Lamothe
President and Chief Executive Officer
2026-08-26